Genomic & Biopharma NewsEU nod for Vifor’s Veltassa
European regulators have approved Vifor Pharma’s new potassium binder Veltassa to treat hyperkalaemia in adult patients.
|PharmaTimes, 2017-07-21 10:48:22|
Tentative US approval for Merck’s diabetes therapy
The US Food and Drug Administration has given a tentative green light to Merck & Co’s follow-on biologic basal insulin Lusduna Nexvue.
|PharmaTimes, 2017-07-21 10:44:31|
Sanofi, Ablynx sign $2.7bn research, licensing pact
Sanofi has signed a research pact and licensing deal with Ablynx that could bring as much as $2.7 billion euros to the Belgian biotech’s coffers if all targets are met.
|PharmaTimes, 2017-07-21 10:40:19|
A sugary drink with a protein-rich meal reduces fat metabolism, study reports
A study published, on 21st July 2017, in the open access journal BMC Nutrition states that consuming a sugar-sweetened drink along with a high-protein meal can have adverse effects on energy balance, change food preferences and reduce fat metabolism.
|News Medical Life Sciences, 2017-07-21 10:12:00|
Mammalian Immunity: Whats RNAi Got to Do with It?
A new study adds to the evidence that mammalian cells can use small interfering RNAs to defend against viruses, but questions remain about physiological importance.
|The Scientist, 2017-07-21 09:20:00|
Amphora raises $36M to trial overactive bladder treatment
Amphora Medical has raised $35.5 million to put its overactive bladder treatment through a pivotal clinical trial. The series B round equips Amphora to take its minimally invasive, cystoscopic device into the last step of clinical development next year.
|Fierce Biotech, 2017-07-21 09:09:08|
Study: Patients discharged from emergency department with AKI remain at increased risk of death
A new study indicates that patients discharged from the emergency department with acute kidney injury (AKI) remain at an increased risk of dying within 30 days. The findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology.
|News Medical Life Sciences, 2017-07-21 08:07:07|
New genomic research partnership promises to redefine and transform cancer treatment
Personalized cancer therapies are on the horizon thanks to a new genomic cancer research partnership between the Gene Editing Institute of Christiana Care Health System's Helen F. Graham Cancer Center & Research Institute and the biotechnology company NovellusDx.
|News Medical Life Sciences, 2017-07-21 07:13:02|
Noninvasive treatment uses cooled radio energy to provide relief from arthritis pain
Pain medicine specialists at Rush have helped develop, and are among the first in the country to provide, a noninvasive treatment for knee arthritis that uses cooled radio energy to target and interrupt pain signals.
|News Medical Life Sciences, 2017-07-21 07:03:42|